Tag: Metabolic & GLP-1
PharmaSignal — Metabolic & GLP-1 therapeutic area
Medicare obesity drug pilot extended after insurer pushback
Pharmaphorum
Medicare will cover the cost of a pilot of weight-loss drug coverage, after health insurers refuse to take part.
Beyond GLP-1Rs: emerging targets poised to gain share of obesity market
Pharmaceutical Technology
Non-GLP-1 obesity drugs are emerging in the market, with this landscape expected to surge 50-fold, generating $15.5bn in 2031.
Lilly’s obesity pill off to a strong start; OpenAI debuts new drug discovery tool
BioPharma Dive
Some 1,390 Foundayo prescriptions were written in two days, according to analysts.
Lilly’s Foundayo reaches 1,390 patients in first week, trailing Novo’s oral Wegovy launch
BioSpace
While Novo Nordisk’s Wegovy pill reached more than 3,000 patients in its first week on the market, analysts at RBC Capital Markets said a direct comparison of the two figures could be misleading given
Novo may have muscle advantage over Lilly in weight-loss race: preprint
BioSpace
More patients on Eli Lilly’s tirzepatide lost over 5% of their lean mass versus those on Novo Nordisk’s semaglutide, according to a study that has yet to be peer reviewed.
Lilly’s new obesity pill passes heart safety test in diabetes
BioPharma Dive
The findings, which come amid FDA scrutiny of Foundayo s safety, will enable Lilly to seek a new clearance in diabetes.
Lilly debuts more Foundayo data as FDA requests post-marketing trials
Pharmaceutical Technology
The FDA requires Eli Lilly to evaluate “unexpected serious” risks associated with Foundayo – some of which have been addressed by the ACHIEVE-4 trial.
Lilly’s Foundayo posts ‘outstanding’ diabetes data, possibly easing FDA safety concerns
BioSpace
Right after the FDA flagged safety concerns for Eli Lilly’s newly approved obesity pill, the pharma posted diabetes data demonstrating a clean safety profile and revealed plans to seek approval in the
Obesity’s explosive growth continues as Q1 deals exceed total 2025 value
BioSpace
Commitments in obesity- and diabetes-focused deals reached $22 billion in the first quarter of 2026–already eclipsing last year’s total of $20.3 billion, according to a new J.P.
Lilly says Foundayo safety confirmed in ACHIEVE-4 trial
Pharmaphorum
Eli Lilly’s ACHIEVE-4 trial results for oral GLP-1 Foundayo set up a filing in diabetes, and provide safety data sought by the FDA.
Lilly’s new obesity pill linked to ‘serious’ safety signals, FDA requests more data
BioSpace
The FDA is asking Eli Lilly to submit cardiovascular and liver safety data from an ongoing Phase 3 trial of Foundayo by July.
Lilly investing billions to prepare for overseas oral GLP-1 launches
BioSpace
With many overseas patients preferring orals to injectables, Eli Lilly has filed for approval of orforglipron in more than 40 countries and is building manufacturing capacity to support the obesity dr
220: An Interview With Dr. Jaime Moore on Obesity Medications and Neuromuscular Disease
Rare Disease Audio
Larry Luxner, senior correspondent for Rare Disease Advisor, interviews Jaime Moore, MD, about weight loss drugs–specifically the role of GLP-1 receptor agonists in treating children with neuromuscula
With oral obesity race underway, all eyes are on Lilly’s Foundayo launch
BioSpace
Novo Nordisk’s oral Wegovy has a few months’ head start on Eli Lilly’s newly approved pill.
Gan & Lee and JW Pharmaceutical agree on bofanglutide commercialisation
Pharmaceutical Business Review
Bofanglutide is a bi-weekly glucagon-like peptide-1 receptor agonist (GLP-1RA) discovered and developed by Gan Lee.
Lilly launches GLP-1 pill, kicking off showdown with Novo Nordisk
BioPharma Dive
After winning the battle for injectable obesity medicines, Lilly hopes Foundayo can help it catch up in the oral market, where Novo has a three-month lead.
23andMe study explains variable results with obesity drugs
Pharmaphorum
Gene variants could explain why some people lose more weight than others with GLP-1 drugs, and why some are more prone to side effects.
Approvals in Hand, Lilly and Novo Obesity Pills Will Battle It Out on Hairline Differences
BioSpace
After Eli Lilly achieved the milestone approval of the weight loss pill Foundayo, Novo Nordisk launched a full-court press to defend oral Wegovy, which has been enjoying a record-breaking launch since
ACC 2026: Meta-analysis supports CagriSema as superior first-line therapy in obesity
Pharmaceutical Technology
KOLs note that CagriSema could cannibalise semaglutide’s market share in obesity due to its improved weight loss and HbA1c reduction efficacy.
Eli Lilly wins FDA approval for weight loss pill, tees up Novo rivalry
Pharmaceutical Technology
Lilly’s product, known under the brand name Foundayo, has a clear route to early blockbuster status.